Literature DB >> 11106327

A modified, optimized kinetic photometric assay for the determination of blood coagulation factor XIII activity in plasma.

L Kárpáti1, B Penke, E Katona, I Balogh, G Vámosi, L Muszbek.   

Abstract

BACKGROUND: Blood coagulation factor XIII (FXIII) is a zymogen that is transformed into an active transglutaminase by thrombin and Ca(2+). FXIII plays an essential role in fibrin stabilization and in the protection of fibrin from proteolytic degradation. No convenient method has been available for the measurement of FXIII activity in plasma. The aim of the present study was to improve and optimize a kinetic photometric FXIII assay originally developed in our laboratory.
METHODS: In the assay, FXIII was activated by thrombin and Ca(2+). Fibrin polymerization was prevented by an inhibitory tetrapeptide. Glycine-ethyl ester and a glutamine residue of a synthetic dodecapeptide served as acyl acceptor and acyl donor transglutaminase substrates, respectively. The amount of ammonia released during the reaction was monitored using glutamate dehydrogenase and NADPH.
RESULTS: The use of a new glutamine substrate and optimization of activator and substrate concentrations increased sensitivity. Substitution of NADPH for NADH and introduction of an appropriate blank eliminated systemic overestimation of FXIII activity. The recovery of FXIII was 96%, the assay was linear up to 470 U/L, the detection limit was 1 U/L, and the imprecision (CV) was <8% even at very low FXIII activities. A reference interval of 108-224 U/L (69-143%) was established. The results correlated well with results obtained by an immunoassay specific for plasma FXIII.
CONCLUSIONS: The optimized FXIII assay is a simple, rapid method for the diagnosis of inherited or acquired FXIII deficiencies and increased FXIII concentrations. It can be easily adapted to clinical chemistry analyzers.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106327

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  11 in total

1.  Evaluating factor XIII specificity for glutamine-containing substrates using a matrix-assisted laser desorption/ionization time-of-flight mass spectrometry assay.

Authors:  Prakash G Doiphode; Marina V Malovichko; Kelly Njine Mouapi; Muriel C Maurer
Journal:  Anal Biochem       Date:  2014-04-19       Impact factor: 3.365

2.  Laboratory Diagnosis of Factor XIII Deficiency in Developing Countries: An Iranian Experience.

Authors:  Akbar Dorgalaleh; Shadi Tabibian; Mahmood Shams; Behnaz Tavasoli; Maryam Gheidishahran; Morteza Shamsizadeh
Journal:  Lab Med       Date:  2016-06-26

3.  Activation of factor XIII is accompanied by a change in oligomerization state.

Authors:  Boris A Anokhin; Vilius Stribinskis; William L Dean; Muriel C Maurer
Journal:  FEBS J       Date:  2017-10-03       Impact factor: 5.542

4.  Role of calcium in the conformational dynamics of factor XIII activation examined by hydrogen-deuterium exchange coupled with MALDI-TOF MS.

Authors:  Ricky T Woofter; Muriel C Maurer
Journal:  Arch Biochem Biophys       Date:  2011-05-26       Impact factor: 4.013

5.  Evaluating the Effects of Fibrinogen αC Mutations on the Ability of Factor XIII to Crosslink the Reactive αC Glutamines (Q237, Q328, Q366).

Authors:  Kelly Njine Mouapi; Lucille J Wagner; Chad A Stephens; Mohammed M Hindi; Daniel W Wilkey; Michael L Merchant; Muriel C Maurer
Journal:  Thromb Haemost       Date:  2019-05-05       Impact factor: 5.249

6.  Effect of factor XIII levels and polymorphisms on the risk of myocardial infarction in young patients.

Authors:  László Balogh; Éva Katona; Zoltán A Mezei; Judit Kállai; Réka Gindele; István Édes; László Muszbek; Zoltán Papp; Zsuzsanna Bereczky
Journal:  Mol Cell Biochem       Date:  2018-02-26       Impact factor: 3.396

7.  The factor XIII-A Val34Leu polymorphism decreases whole blood clot mass at high fibrinogen concentrations.

Authors:  Sravya Kattula; Zsuzsa Bagoly; Noémi Klára Tóth; László Muszbek; Alisa S Wolberg
Journal:  J Thromb Haemost       Date:  2020-02-28       Impact factor: 5.824

8.  Factor XIII B subunit polymorphisms and the risk of coronary artery disease.

Authors:  Zoltán A Mezei; Zsuzsanna Bereczky; Éva Katona; Réka Gindele; Emília Balogh; Szilvia Fiatal; László Balogh; István Czuriga; Róza Ádány; István Édes; László Muszbek
Journal:  Int J Mol Sci       Date:  2015-01-06       Impact factor: 5.923

9.  Intracardiac Hemostasis and Fibrinolysis Parameters in Patients with Atrial Fibrillation.

Authors:  Noémi Klára Tóth; Zoltán Csanádi; Orsolya Hajas; Alexandra Kiss; Edina Nagy-Baló; Kitti Bernadett Kovács; Ferenc Sarkady; László Muszbek; Zsuzsanna Bereczky; László Csiba; Zsuzsa Bagoly
Journal:  Biomed Res Int       Date:  2017-06-21       Impact factor: 3.411

10.  Low factor XIII levels after intravenous thrombolysis predict short-term mortality in ischemic stroke patients.

Authors:  Edina Gabriella Székely; Katalin Réka Czuriga-Kovács; Zsuzsanna Bereczky; Éva Katona; Zoltán András Mezei; Attila Nagy; Noémi Klára Tóth; Ervin Berényi; László Muszbek; László Csiba; Zsuzsa Bagoly
Journal:  Sci Rep       Date:  2018-05-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.